Adoptively transferable tolerance induced by CD45RB monoclonal antibody

Journal of the American Society of Nephrology

Volumn 10, Issue 2, 1999, Pages 374-381

  Gao, Zuhua ^a   Zhong, Robert ^a   Jiang, Jifu ^a   Garcia, Bertha ^a   Xing, Jing Jing ^a   White, Martin J ^a   Lazarovits, Andrew I ^a  

^a LONDON HEALTH SCIENCES CENTRE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CD45 ANTIGEN; MONOCLONAL ANTIBODY;

ADOPTIVE TRANSFER; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; IMMUNOLOGICAL TOLERANCE; IMMUNOMODULATION; IMMUNOREGULATION; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MALE; MOUSE; NONHUMAN; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL;

EID: 0032904292     PISSN: 10466673     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (73)

1. Suthanthiran M, Strom TB: Renal transplantation. N Engl J Med 331: 365-376, 1994
2. Hall BM: Cells mediating allograft rejection. Transplantation 51: 1141-1151, 1991
3. Abramowicz D, Schandene L, Goldman M, Crusiaux A, Vereerstraeten P, DePauw L, Wybran J, Kinnaert P, Dupont E, Toussaint C: Release of tumor necrosis factor, interleukin-2, and gamma-interferon in serum after injection of OKT3 monoclonal antibody in kidney transplant recipients. Transplantation 47: 606-608, 1989
4. Swinnen LJ, Costanzo-Nordin MR, Fisher SG, O'Sullivan EJ, Johnson MR, Heroux AL, Dizikes GJ, Pifarre R, Fisher RI: Increased incidence of lymphoproliferative disorder after immunosuppression with the monoclonal antibody OKT3 in cardiac transplant recipients. N Engl J Med 323: 1723-1728, 1990
5. Chatenoud L, Ferran C, Reuter A, Legendre C, Gevaert Y, Kreis H, Franchimont P, Bach JF: Systemic reaction to the anti-T cell monoclonal antibody OKT3 in relation to serum levels of tumor necrosis factor and interferon a. N Engl J Med 320: 1420-1421, 1989
6. Gaston RS, Deierhoi MH, Patterson T, Prasthofer E, Julian BA, Barber WH, Laskow DA, Diethelm AG, Curtis JJ: OKT3 first-dose reaction: Association with T cell subsets and cytokine release. Kidney Int 39: 141-148, 1991
7. Cosimi AB: The clinical usefulness of antilymphocyte antibodies. Transplant Proc 15: 583-589, 1983
8. Kupin WL, Venkatachalam KK, Oh HK, Dienst S, Levin NW: Sequential use of Minnesota antilymphoblast globulin and cyclosporine in cadaveric renal transplantation. Transplantation 40: 601-604, 1985
9. Ortho Multicenter Transplant Study Group: A randomized clinical trial of OKT3 monoclonal antibody for acute rejection of cadaveric renal transplants. W Engl J Med 313: 337-342, 1985
10. Kirkman RL, Araujo JL, Busch GJ, Carpenter CB, Milford EL, Reinherz EL, Schlossman SF, Strom TB, Tilney NL: Treatment of acute renal allograft rejection with monoclonal anti-T12 antibody. Transplantation 36: 620-626, 1983
11. Jonker M, Goldstein G, Balner H: Effects of in vivo administration of monoclonal antibodies specific for human T cell subpopulations on the immune system in a rhesus monkey model. Transplantation 35: 521-526, 1983
12. Shizuru JA, Gregory AK, Chao CT, Fathman CG: Islet allograft survival after a single course of treatment of recipient with antibody to L3T4. Science (Washington DC) 237: 278-280, 1987
13. Cosimi AB, Conti D, Delmonico FL, Preffer FI, Wee SL, Rothlein R, Faanes R, Colvin RB: In vivo effects of monoclonal antibody to ICAM-1 (CD54) in nonhuman primates with renal allografts. J Immunol 144: 4604-4612, 1990
14. Hale G, Waldmann H, Friend P, Calne R: Pilot study of CAMPATH-1, a rat monoclonal antibody that fixes human complement, as an immunosuppressant in organ transplantation. Transplantation 42: 308-311, 1986
15. Cosimi AB, Burton RC, Kung PC, Colvin RB, Goldstein G, Lifter J, Rhodes W, Russell PS: Evaluation in primate renal allograft recipients of monoclonal antibody to human T cell subclasses. Transplant Proc 13: 499-503, 1981
16. Soulillou JP, Cantarovich D, LeMauff B, Girai M, Robillard N, Hourmant M, Hirn M, Jacques Y: Randomized controlled trial of a monoclonal antibody against the interleukin-2 receptor (33B3.1) as compared with rabbit antithymocyte globulin for prophylaxis against rejection of renal allografts. N Engl J Med 322: 1175-1182, 1990
17. Kirkman RL, Shapiro ME, Carpenter CB, McKay DB, Milford EL, Ramos EL, Tilney NL, Waldmann TA, Zimmerman CE, Strom TB: A randomized prospective trial of anti-TAC monoclonal antibody in human renal transplantation. Transplantation 51: 107-113, 1991
18. Norman DJ, Kahana L, Stuart FP, Thistlethwaite JR, Shield CF III, Monaco A, Dehlinger J, Wu SC, Van Horn A, Haverty TP: A randomized clinical trial of induction therapy with OKT3 in kidney transplantation. Transplantation 55: 44-50, 1993
19. Lazarovits AI, Rochon J, Banks L, Hollomby DJ, Muirhead N, Jevnikar AM, White MJ, Amlot PL, Beauregard-Zollinger L, Stiller CR: Human mouse chimeric CD7 monoclonal antibody (SDZCHH380) for the prophylaxis of kidney transplant rejection. J Immunol 150: 5163-5174, 1993
20. Nashan B, Moore R, Amlot P, Schmidt AG, Abeywickrama K, Soulillou JP: Randomised trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients. Lancet 350: 1193-1198, 1997
21. Vincenti F, Kirkman R, Light S, Bumgardner G, Pescovitz M, Halloran P, Neylan J, Wilkinson A, Ekberg H, Gaston R, Backman L, Burdick J: Interleukin-2 receptor blockade with daclizumab to prevent acute rejection in renal transplantation. N Engl J Med 338: 161-165, 1998
22. Fabre JW, Williams AF: Quantitative serological analysis of a rabbit anti-rat lymphocyte serum and preliminary biochemical characterization of the major antigen recognized. Transplantation 23: 349-359, 1977
23. Fabre JW, Sunderland CA, Williams AF: Immunosuppressive properties of rabbit antibodies against a major glycoprotein restricted to rat leukocyte membranes. Transplantation 30: 167-173, 1980
24. Warr GW, Marchalonis JJ: Glycoproteins of murine thymocyte and splenocyte surface membranes: Binding to concanavalin A and recognition by heterologous antilymphocyte serum. Immunochemistry 13: 753-758, 1976
25. Bonnefoy-Berard N, Vincent C, Revillard JP: Antibodies against functional leukocyte surface molecules in polyclonal antilymphocyte and antithymocyte globulins. Transplantation 51: 669-673, 1991
26. Rebellato LM, Gross U, Verbanac KM, Thomas JM: A comprehensive definition of the major antibody specificities in polyclonal rabbit antithymocyte globulin. Transplantation 57: 685-694, 1994
27. Lazarovits AI, Poppema S, White MJ, Karsh J: Inhibition of alloreactivity in vitro by monoclonal antibodies directed against restricted isoforms of the leukocyte-common antigen (CD45). Transplantation 54: 724-729, 1992
28. lck by the CD45 phosphotyrosine phosphatase. Proc Natl Acad Sci USA 86: 6302-6306, 1989
29. Tonks NK, Diltz CD, Fischer EH: CD45, an integral membrane protein tyrosine phosphatase. J Biol Chem 265: 10674-10680, 1990
30. Fischer EH, Charbonneau H, Tonks NK: Protein tyrosine phosphatases: A diverse family of intracellular and transmembrane enzymes. Science (Washington DC) 253: 401-406, 1991
31. Trowbridge IS, Thomas ML: CD45: An emerging role as a protein tyrosine phosphatase required for lymphocyte activation and development. Annu Rev Immunol 12: 85-116, 1994
32. McKeon F: When worlds collide: Immunosuppressants meet protein phosphatases. Cell 66: 823-826, 1991
33. Hathcock KS, Laszlo G, Dickler HB, Sharrow SO, Johnson P, Trowbridge IS, Hodes RJ: Expression of variable exon A-, B-, and C-specific CD45 determinants on peripheral and thymic T cell populations. J Immunol 148: 19-28, 1992
34. Merkenschlager M: Confusion over CD45 isoform [Letter; Comment]. Nature (Lond) 352: 28, 1991
35. Brooks CG, Holscher M: Cell surface molecules involved in NK recognition by cloned cytotoxic T lymphocytes. J Immunol 138: 1331-1337, 1987
36. Ledbetter JA, Tonks NK, Fischer EH, Clark EA: CD45 regulates signal transduction and lymphocyte activation by specific association with receptor molecules on T or B cells. Proc Natl Acad, Sci USA 85: 8628-8632, 1988
37. Lefrancois L, Bevan MJ: Functional modifications of cytotoxic T lymphocyte T200 glycoprotein recognized by monoclonal antibodies. Nature (Lond) 314: 449-452, 1985
38. Takeuchi T, Rudd CE, Schlossman SF, Morimoto C: Induction of suppression following autologous mixed lymphocyte reaction: role of a novel SH4 antigen. Eur J Immunol 17: 97-103, 1987
39. Harvath L, Balke JA, Christiansen NP, Russell AA, Skubitz KM: Selected antibodies to leukocyte common antigen (CD45) inhibit human neutrophil chemotaxis. J Immunol 146: 949-957, 1991
40. Bernabeu C, Carrera AC, DeLandazuri MO, Sanchez-Madrid F: Interaction between the CD45 antigen and phytohemagglutinin: Inhibitory effect on the lectin-induced T cell proliferation by anti-CD45 monoclonal antibody. Eur J Immunol 17: 1461-1466, 1987
41. Pingel JT, Thomas ML: Evidence that the leukocyte common antigen is required for antigen induced T lymphocyte proliferation. Cell 58: 1055-1065, 1989
42. - thymocytes. J Immunol 143: 2425-2430, 1989
43. Morimoto C, Letvin NL, Distaso JA, Aldrich WR, Schlossman SF: The isolation and characterization of the human suppressor inducer T cell subset. J Immunol 134: 1508-1515, 1985
44. Morimoto C, Letvin NL, Boyd AW, Hagan M, Brown HM, Kornacki MM, Schlossman SF: The isolation and characteriza tion of the human helper inducer T cell subset. J Immunol 134: 3762-3769, 1985
45. Sanders ME, Makgoba MW, Sharrow SO, Stephany D, Springer TA, Young HA, Shaw S: Human memory T lymphocytes express increased levels of three cell adhesion molecules (LFA-3 CD2, and LFA-2) and three other molecules (UCHL1, CDw29 and Pgp-1) and have enhanced IFN-γ production. J Immunol 140: 1401-1407, 1988
46. Serra HM, Krowka JF, Ledbetter A, Pilarski LM: Loss of CD45R (Lp220) represents a post-thymic T cell differentiation event. J Immunol 140: 1435-1441, 1988
47. Akbar AN, Terry L, Timms A, Beverley PCL, Janossy G: Loss of CD45R and gain of UCHL1 reactivity is a feature of primed T cells. J Immunol 140: 2171-2178, 1988
48. Brod SA, Rudd CE, Purvee M, Hafler DA: Lymphokine regulation of CD45R expression on human T cell clones. J Exp Med 170: 2147-2152, 1989
49. Bell EB, Sparshott SM: Interconversion of CD45R subsets of CD4 T cells in vivo. Nature (Lond) 348: 163-166, 1990
50. + cells after activation with Con A. Cell Immunol 129: 449-467, 1990
51. + T cell line. J Immunol 146: 1175-1183, 1991
52. Stamenkovic I, Sgroi D, Aruffo A, Sy MS, Anderson T: The B lymphocyte adhesion molecule CD22 interacts with leukocyte common antigen CD45RO on T cells and alpha 2-6 silyltransferase, CD75, on B cells. Cell 66: 1133-1144, 1991
53. Aruffo A, Kanner SB, Sgroi D, Ledbetter JA, Stamenkovic I: CD22-mediated stimulation of T cells regulates T-cell receptor/CD3-induced signaling. Proc Natl Acad Sci USA 89: 10242-10246, 1992
54. Engel P, Nojima Y, Rothstein D, Zhou LJ, Wilson GL, Kehrl JH, Tedder TF: The same epitope on CD22 of B lymphoctyes mediates the adhesion of erythrocytes, T and B lymphocytes, neutrophils, and monocytes. J Immunol 150: 4719-4732, 1993
55. Clark EA: CD22, a B cell-specific receptor, mediates adhesion and signal transduction. J Immunol 150: 4715-4718, 1993
56. Birkeland ML, Johnson P, Trowbridge IS, Pure E: Changes in CD45 isoform expression accompany antigen-induced murine T-cell activation. Proc Natl Acad Sci USA 86: 6734-6738, 1989
57. Poppema S, Lai R, Visser L: Antibody MT3 is reactive with a novel exon B-associated 190-kDa sialic acid dependent epitope of the leukocyte common antigen complex. J Immunol 147: 218-223, 1991
58. + T cells are important for the balance between protective and pathogenic cell-mediated immunity. J Exp Med 179: 589-600, 1994
59. Mosmann TR, Coffman RL: TH1 and TH2 cells: Different ; patterns of lymphokine secretion lead to different functional properties. Annu Rev Immunol 7: 145-173, 1989
60. Lazarovits AI, Poppema S, Zhang Z, Khandaker M, LeFeuvre CE, Singhal SK, Garcia BM, Ogasa N, Jevnikar AM, White MJ, Singh G, Stiller CR, Zhong RZ: Prevention and reversal of renal allograft rejection by antibody against CD45RB. Nature (Lond) 380: 717-720, 1996
61. Zhang Z, Zhu LF, Quan D, Garcia B, Ozcay N, Duff J, Stiller C, Lazarovits A, Grant D, Zhong R: Pattern of liver, kidney, heart, and intestine allograft rejection in different mouse strain combinations. Transplantation 62: 1267-1272, 1996
62. Pohanka E, Zlabinger GJ, Mayer G, Woloszcsuk W, Kovarik J, Smolen J, Steffen C: Comparison of serum neopterin levels and spontaneous blastogenesis in monitoring of kidney graft recipients. Transplant Proc 20: 110-115, 1988
63. Onodera K, Hancock WW, Graser E, Lehmann M, Sayegh MH, Strom TB, Volk HD, Kupiec-Weglinski JW: Type 2 helper T cell-type cytokines and development of "infectious" tolerance in rat cardiac allograft recipients. J Immunol 158: 1572-1581, 1997
64. Hedman H, Branden H, Lundgren E: Physical separation of ICAM-1 binding cells. J Immunol Methods 146: 203-211, 1992
65. Basadonna GP, Auersvald L, Khuong CQ, Zheng XX, Kashio N, Zekzer D, Minozzo M, Qian HY, Visser L, Diepstra A, Lazarovits AI, Poppema S, Strom TB, Rothstein DM: Antibody-mediated targeting of CD45 isoforms: A novel immunotherapeutic strategy. Proc Natl Acad Sci USA 95: 3821-3826, 1998
66. Lazarovits AI, Osman N, LeFeuvre CE, Ley SC, Crumpton MJ: CD7 is associated with CD3 and CD45 on human T cells. J Immunol 153: 3956-3966, 1994
67. D'Adamio F, Zollo O, Moraca R, Ayroldi E, Bruscoli S, Bartoli A, Cannarile L, Migliorati G, Riccardi C: A new dexamethasone-induced gene of the leucine zipper family protects T lymphocytes from TCR/CD3-activated cell death. Immunity 7: 803-812, 1997
68. Davies JD, Martin G, Phillips J, Marshall SE, Cobbold SP, Waldmann H: T cell regulation in adult transplantation tolerance. J Immunol 157: 529-533, 1996
69. Mohler KM, Streilein JW: Lymphokine production by MLR-reactive reaction lymphocytes obtained from normal mice and mice rendered tolerant of class II MHC antigens. Transplantation 47: 625-633, 1989
70. Parry N, Lazarovits AI, Wang J, Garcia B, Luke P, Poppema S, Zhong R: Cyclosporine inhibits long-term survival in cardiac allografts treated with monoclonal antibody against CD45RB. J Heart Lung Transplant 1999, in press
71. Gajewski TF, Qian D, Fields P, Fitch FW: Anergic T lymphocyte clones have altered inositol phosphate, calcium and tyrosine kinase signaling pathways. Proc Natl Acad Sci USA 91: 38-42, 1994
72. Quill H: Anergy as a mechanism of peripheral T cell tolerance. J Immunol 156: 1325-1327, 1996
73. Lombardi G, Sidhu S, Batchelor R, Lechler R: Anergic T cells as suppressor cells in vitro. Science (Washington DC) 264: 1587-1589, 1994